While continuous ambulatory peritoneal dialysis (CAPD) is often the treatment of choice, dialysis solutions present a glycaemic challenge to diabetics and regular monitoring is essential
Diabetes (Type I and II) is the most important cause of systemic renal disease and therefore many of the patients admitted to renal units are diabetics requiring intervention to ensure adequate renal perfusion and minimise irreversible damage.
While continuous ambulatory peritoneal dialysis (CAPD) is often the treatment of choice, dialysis solutions present a glycaemic challenge to diabetics and regular monitoring is essential to ensure adequate control of blood glucose levels.
However, the Icodextrin found in CAPD solutions has been shown to interfere with glucose strip readings, generating erroneously high results and leading to potentially fatal treatment decisions.
With an error of +/-20% and known to be affected by a range of drugs and other factors, strip technology is clearly unsuitable for monitoring in the renal unit where precise, accurate results are required to ensure patient safety.
HemoCue Glucose 201 is a compact and easy to use device that provides the precision and accuracy (+/- 2%) of laboratory analysers, making it the only point of care testing device that meets the exacting requirements of renal units.
Calibrated to international standards with guaranteed precision and accuracy, the device is unaffected by interfering substances giving on the spot results that clinicians can depend on.
